![]() | ![]() |
Formats:
|
||||||||||||||||||||
Copyright © 2008, The American Society for Biochemistry and
Molecular Biology, Inc. ‡Laboratorium voor Ultrastructuur, Vrije Universiteit Brussel, Pleinlaan 2, B-1050 Brussel, Belgium, the §Department of Molecular and Cellular Interactions, Vlaams Interuniversitair Instituut voor Biotechnologie (VIB), Pleinlaan 2, B-1050 Brussel, Belgium, the ¶Institute for Cell and Molecular Biosciences, Medical School, Newcastle University, Newcastle NE2 4HH, United Kingdom, the Department of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark, the **Laboratory of Biochemistry and Molecular Biology, NCI, National Institutes of Health, Bethesdam, Maryland 20892-4255, and the ‡‡Department of Biological Sciences, University of Alabama in Huntsville, Huntsville, Alabama 358991
To whom correspondence should be addressed. Tel.: 32-2-6291989; Fax:
32-2-6291963; E-mail:
reloris/at/vub.ac.be.
Received July 23, 2008; Revised August 26, 2008. This article has been cited by other articles in PMC.Abstract Prokaryotic toxin-antitoxin modules are involved in major physiological
events set in motion under stress conditions. The toxin Doc (death
on curing) from the phd/doc module on phage P1
hosts the C-terminal domain of its antitoxin partner Phd (prevents
host death) through fold complementation. This Phd
domain is intrinsically disordered in solution and folds into an α-helix
upon binding to Doc. The details of the interactions reveal the molecular
basis for the inhibitory action of the antitoxin. The complex resembles the
Fic (filamentation induced by cAMP) proteins and suggests a possible
evolutionary origin for the phd/doc operon. Doc induces growth arrest
of Escherichia coli cells in a reversible manner, by targeting the
protein synthesis machinery. Moreover, Doc activates the endogenous E.
coli RelE mRNA interferase but does not require this or any other known
chromosomal toxin-antitoxin locus for its action in vivo. Small operons encoding a toxin and its antitoxin are common in the genomes
of bacteria and archaea and are also found on certain plasmids and
bacteriophages. These so-called toxin-antitoxin
(TA)2 modules have
been proposed to regulate the pace of metabolism and may induce a state of
dormancy in case of nutritional stress
(1–3).
TA modules are highly abundant in opportunistic pathogens such as
Mycobacterium tuberculosis
(4), and their presence has
been linked to persistence
(5). On plasmids, TA modules act as addiction systems, aiding plasmid
maintenance in the bacterial population by post-segregational killing
(6), filling in a function
related to apoptosis and programmed cell death in eukaryotes
(7). Related effects have been
observed for chromosome-located TA systems as some of them have been shown to
diminish large scale genome reductions in the absence of selection
(8). In the presence of the
plasmid, both toxin and antitoxin are expressed, leading to a steady state
equilibrium where the antitoxin counteracts the effect of the toxin. In its
free state, the antitoxin, usually a modular protein that contains a
functional intrinsically disordered region
(9–11),
is under constant proteolytic attack. The toxin-antitoxin complex acts as an
autorepressor for the TA operon, ensuring that only small amounts of the
proteins are present in the cell. Upon plasmid loss, the antitoxin is degraded
by a specific intracellular protease, releasing the toxin. Without the
possibility of replenishing the antitoxin population, the toxin action becomes
irreversible, resulting in cell death. The phd/doc operon encodes a TA module aiding the maintenance of
the plasmid-prophage P1 in Escherichia coli
(12). Doc is an inhibitor of
translation elongation through its association with the 30 S ribosomal subunit
in a way similar to the antibiotic hygromycin
(13). The action of Doc is
suppressed by the antitoxin Phd, which consists of two domains. Its C-terminal
domain (residues 52–73) harbors the interaction site with Doc and on its
own prevents Doc-mediated growth arrest
(14,
15). The N-terminal region
(residues 1–51) of Phd is a dimerization/DNA-binding domain that binds
to the operator site of the phd/doc operon. Phd forms a
heterotrimeric complex with Doc
(16). Operator binding and
repression of the phd/doc operon by Phd are enhanced by the presence
of Doc in a cooperative manner
(17–19). Here we present the crystal structure of a non-toxic version of Doc
(DocH66Y, an H66Y mutant of Doc) in complex with the C-terminal
domain of Phd (Phd52–73Se, a peptide corresponding to
residues 52–73 of Phd with Se-Met substituted for Leu-52 and Leu-70) and
provide further information on the interplay between Doc and endogenous
chromosomal TA modules. The structure reveals a new all α-helical fold,
leads to new insights into the molecular action of Doc and its interaction
with Phd, and suggests a possible origin for the phd/doc module. EXPERIMENTAL PROCEDURES Crystal Structure Determination—Purification of
DocH66Y and crystallization of DocH66Y and of its
complex with Phd52–73Se (C-terminal 22 residues of Phd with
Leu-52 and Leu-70 substituted to Se-Met) are reported
elsewhere.3 After a
failed attempt to phase the structure of
DocH66Y-Phd52–73Se using the two Se-methionines
present in Phd52–73Se, a crystal was soaked for about 3 min
in a cryo-protecting solution (0.2 m NaCl, 0.1 m sodium
acetate, pH 4.6, and 35% 2-methyl-2,4-pentanediol) enriched with 1.5
m of NaBr. Data were collected at the K-edge of bromine and at a
high energy remote wavelength (Table
1). The data sets were indexed, integrated, and merged using the
HKL suite of programs (20).
Substructure calculation with ShelxD
(21) detected 17 potential
bromine sites. Phases were calculated by two-wavelength multiwavelength
anomalous dispersion using the software pipeline AutoRickshaw
(22). The experimentally
phased electron density map allowed automated building of the model with
ARP/wARP (23) after 2-fold
symmetry averaging of the electron density based upon non-crystallographic
symmetry parameters derived from the known heavy atom positions. The resulting
model was highly complete and refined using REFMAC5
(24) to an
Rfree factor of 19.8% and a conventional R-factor
of 18.3%. Details of data collection and refinement statistics are given in
Table 1.
CD Spectropolarimetry—Far UV-CD spectra were recorded on a
J-715 spectropolarimeter (Jasco). Scans were taken using a 0.1-cm cuvette. The
temperature of the cuvette was monitored using a probe, and a water bath was
used for maintaining the temperature of the sample constant. The measurements
were performed at 298 K, in 50 mm Tris (pH 7.5), 150 mm
sodium chloride. Spectra of DocH66Y and Phd52–73Se
were taken using a protein concentration of 60 μm. For the
spectrum of the complex, DocH66Y and Phd52–73Se
were mixed in equimolar ratio to a final concentration of 60 μm
of the complex and preincubated for 5 min before taking the spectrum. The mean
residue ellipticities ([θ], degrees cm2 mol-1)
were obtained from the raw data (θ, ellipticity) after correcting for
the buffer solution, according to [θ] =
θ·Mw/(n·c·l), where Mw
is the molecular weight, c is the mass concentration, l is
the optical path length, and n is the number of amino acid
residues. Northern Blotting and Primer Extension Analyses—Strains and
plasmids used in this work are described in the supplemental Materials and
Methods and are summarized in supplemental Table S1. Cells were grown in LB at
37 °C. At an A450 of 0.5, the cultures were diluted 10
times and grown to an OD of 0.5. Transcription of the toxins was induced by
the addition of arabinose to 0.2%. To inhibit translation, chloramphenicol (50
μg/ml) was added. For Northern analysis, total RNA was fractionated by PAGE
(6% bis-acrylamide), blotted to a Zeta-Probe nylon membrane, and hybridized
with a single-stranded 32P-labeled riboprobe, complementary to the
RNA. The radioactive probe was generated using linearized plasmid DNA of
pSC333 constructing probes for lpp mRNA. Semiquantitative primer
extension analysis was performed essentially according to the method
previously described (25). The
stop codons of mRNAs originating from pKW254T derivatives were mapped with the
primer pKW71D-3#PE, which is complementary to the linker RNA of pKW254T. The
primers lpp 21 and lpp 26 were used to map the 5′ end of lpp
mRNA. The 5′ end of dksA mRNA was mapped using the primer dksA
PE1. The complete list of oligonucleotides used is given in supplemental Table
S2. RESULTS Structure of DocH66Y—Because of difficulties in
producing sufficient amounts of wild-type Doc, we used the less toxic mutant
H66Y (19) for structure
determination. DocH66Y was crystallized in complex with a peptide
encompassing the C-terminal 22 amino acids of Phd with Se-Met substituted for
Leu-52 and Leu-70 (Phd52–73Se). This fragment was chosen
based upon previous work that delineates the toxin-binding domain of Phd
(14,
15). The Doc protein shows an
all-α-helical fold consisting of six α-helices
(Fig. 1
Multiple sequence alignment of Doc family members reveals a single highly
conserved motif, HXFX(D/E)(A/G)N(K/G)R. It is located in the
loop α3-α4 (residues 66–74)
(Fig. 1
Interactions with Phd—The C-terminal domain of Phd on its
own is sufficient to protect against Doc
(14,
15).
Phd52–73Se binds into a groove of DocH66Y of which
helix α4 forms the base and that is flanked by helix α1 on one
side and the loop α4-α5 on the other side
(Fig. 1A Far UV CD experiments show that Phd52–73Se is
intrinsically unstructured in its isolated state but gains an appreciable
amount of α-helix upon binding to Doc
(Fig. 3
The C-terminal segment of Phd52–73Se is highly hydrophilic
and provides only a single hydrophobic residue (Leu-70 in Phd, Se-Met-70 in
Phd52–73Se) to the binding interface. This residue makes
extensive contacts with a small hydrophobic cavity on the Doc surface
(Fig. 4B It should be noted here that although the C terminus of
Phd52–73Se is adjacent to the surface cluster of conserved
residues, the conserved sequence motif of Doc is not part of the Phd-binding
site. This indicates that Phd52–73Se counteracts the toxic
activity of Doc either by inducing a conformational change in Doc or by
sterically preventing Doc to interact with the ribosome. Both mechanisms have
been proposed earlier on for other TA modules
(27,
28). Doc Has an Incomplete Fic Fold—Structural similarity
searches against the Structural Classification of Proteins-(SCOP) data base
using the DALI server failed to reveal any protein with significant similarity
to Doc. However, all Doc homologues possesses a conserved central motif (see
above) of 9 residues that is shared with two other protein families: the
bacterial cAMP-induced filamentation protein (Fic) and a domain of the
eukaryotic Huntingtin Yeast Protein E (HYPE) protein
(29). Sequence similarity
between Doc and these other two protein families outside this 9-residue region
is very weak with overall sequence identities below 15%. A query of the Protein Data Bank with the conserved central motif of Doc
resulted in the identification of two proteins that show a high structural
similarity to Doc. These otherwise undescribed recent depositions from the
Midwest Center for Structural Genomics are crystal structures of two Fic
proteins: Fic_Hp from Helicobacter pylori (PDB entry 2F6S) and Fic_Nm
from Neisseria meningitidis (PDB entry 2G03). Fic_Nm is the most
closely related to Doc with an root mean square deviation of 2.3 Å for
105 matching Cα atoms (Z score 6.7)
(Fig. 5A
Fic in most respects resembles the architecture of Doc, including very
similar conformations for the conserved central motif in loop
α3-α4, suggesting a common evolutionary origin (supplemental Fig.
S2). Also, His-13, the residue that in Doc anchors the conserved central
motif, is conserved and makes equivalent interactions in all structures
(supplemental Fig. S2). Nevertheless, Fic differs from Doc by the presence of
an extra N-terminal α-helix, by an insertion in the loop
α1-α2, and most importantly, by an additional C-terminal
α-helix (Fig.
5A Based upon these observations, we propose that Doc evolved from a Fic-like
ancestor of which the C-terminal α-helix was transferred to a
DNA-binding domain, thereby generating the antitoxin Phd. Upon binding, the
antitoxin donates an α-helix to form the complex thereby complementing
the fold. Doc Induces Growth Arrest but Not Cell Death—Induction of
Doc leads to growth arrest within the doubling time of E. coli.
However, the cells do not lyse and remain motile for several hours after
induction, when examined under a light microscope. This indicates an intact
cell membrane and a working proton motive force. We do not observe
filamentation in cells in which Doc has been activated, although filamentation
but not induction of the SOS pathway was reported earlier
(12). The observed growth
arrest is reversible as cells replated in the absence of IPTG are capable of
colony formation for several hours after the start of IPTG induction. We
further confirmed that Doc arrests bulk protein synthesis but not RNA or DNA
synthesis (Fig. 6
Doc Induces RelE-mediated Cleavage of Model mRNAs—A recent
study showed that Doc expression in E. coli strain BL21(DE3) led to
mRNA stabilization (13). By
contrast, we observe destabilization of two different model mRNAs
(lpp and dksA) after induction of doc in E.
coli strain MG1655 (Fig.
7A
DISCUSSION The phd/doc locus of prophage P1 is an archetype member of a
family of toxin-antitoxin modules found also on bacterial chromosomes.
Although first reported in 1993
(12), phd/doc has
remained less understood than the well known ccdAB, relBE and
mazEF modules. Here we show that the toxin Doc adopts an
all-α-helical fold different from the folds of other TA toxins with
known structure. Doc contains a single highly conserved surface patch distinct
from its interaction site with the antitoxin Phd. The significance of this
conserved surface region is corroborated by the observation that Doc resembles
members of another family of bacterial proteins called Fic, that a signature
sequence present in the conserved surface region of Doc is also conserved in
Fic, and that mutations within this motif affect Doc toxicity. This is
indicative of a functionally relevant site and suggests that the mechanisms of
action of Doc and Fic are related. Doc has been shown to inhibit protein synthesis and to associate with the
70 S ribosome and with the 30 S ribosomal subunit
(13). The mechanism of action
of Fic is currently unknown. The strong structural similarities between both
proteins and the presence of a highly conserved and functionally important
region raise the possibility that Fic is also capable of halting translation
on the ribosome or to modify ribosomal activity. Available data indicate that
Fic has a role in cell division
(33), most likely under the
tight control of the cell division machinery. Mutations of Fic, such as G55R
(34), may distort this
control, leading to its accidental activation
(12,
33). We suggest that Doc
evolved from a mutant of a Fic-like ancestor defective in regulation of its
activity. Likely, the C terminus of such an ancestor of Doc was transferred to
a DNA-binding domain. This resulted in a novel regulatory system that by its
ability to be used for conditional killing or growth arrest can function as a
plasmid addiction module and as a TA stress operon. The existence of several
open reading frames of doc-like genes fused to genes encoding DNA-binding
domains among different bacterial genomes favors this hypothesis. Further
studies are nevertheless required to substantiate this hypothesis. During complex formation, Phd donates its C-terminal domain to complement
the truncated Fic-like fold of Doc. Fold complementation has been described as
one of the major mechanisms by which proteins can bind peptides in a
β-strand conformation
(35). As a result of the
complex formation, the added β-strand complements for a missing secondary
structure element in an otherwise incomplete fold. The completion of an
Ig-like β-sandwich in the subunit-subunit and chaperone-subunit
interactions in bacterial pili assembled by the chaperoneusher pathway and the
addition of the hepatitis C virus NS4A cofactor peptide to the N-terminal
β-sheet in the NS3 protease that complements a chymotrypsin-like fold are
classical examples of this mechanism
(36,
37). To our knowledge, this
mechanism has not been observed before for α-helical peptide ligands
binding to all-α-helical proteins. The amphipathic nature of the
α-helix of Phd and the hydrophobic surface patch at the center of the
Phd-binding site on Doc are likely remnants of the Fic-like ancestor of Doc,
which had its hydrophobic core partially disrupted when it lost its C
terminus. Our in vivo experiments indicate that the ectopic overexpression
of Doc can induce the mRNA interferase activity of RelE, a chromosomal TA
toxin of E. coli. Activation of RelE, together with MazF, is
triggered by stress conditions and is probably part of the general response of
the cell to internal alarm signals. RelE activation may be an attempt of the
cells to relieve the stress induced by Doc-mediated translation arrest.
Indeed, RelE activity correlates with tmRNA activity
(38). Thus, mRNA degradation
on Doc-arrested ribosomes may mimic translation quality control systems that
are invoked when termination of translation fails. [Author Profile]
Acknowledgments We acknowledge the use of beam time at the European Molecular Biology
Laboratory (EMBL) beamlines at the Deutsches Elektronen-Synchrotron (DESY)
synchrotron (Hamburg, Germany). Notes The atomic coordinates and structure factors (code 3dd7) have been
deposited in the Protein Data Bank, Research Collaboratory for Structural
Bioinformatics, Rutgers University, New Brunswick, NJ
(http://www.rcsb.org/). *This work was supported, in whole or in part, by National
Institutes of Health Grant 2
R15 GM67668-03 from the
NIGMS (to R. D. M.) and a
National Institutes of Health Intramural Research Training
Award grant. This work was also supported
by grants from the VIB,
the Fonds voor Wetenschappelijk Onderzoek
Vlaanderen, the Centre for
mRNP Biogenesis and Metabolism of the Danish National Research
Foundation, and the
Onderzoeksraad of the Vrije Universiteit
Brussel. The costs of publication of this
article were defrayed in part by the payment of page charges. This article
must therefore be hereby marked “advertisement” in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact. The on-line version of this article (available at
http://www.jbc.org)
contains supplemental Materials and Methods, four supplemental figures, two
supplemental tables, and supplemental references.♦This article was selected as a Paper of the Week. Footnotes 2The abbreviations used are: TA, toxin-antitoxin; PDB, Protein Data Bank;
IPTG, isopropyl-1-thio-β-d-galactopyranoside. 3A. Garcia-Pino and R. Loris, manuscript in preparation. References 1. Buts, L., Lah, J., Dao-Thi, M. H., Wyns, L., and Loris, R.
(2005. ) Trends Biochem. Sci
30 672-679 [PubMed] 2. Gerdes, K., Christensen, S. K., and Lobner-Olesen, A.
(2005. ) Nat. Rev. Microbiol.
3 371-382 [PubMed] 3. Pedersen, K., Christensen, S. K., and Gerdes, K.
(2002. ) Mol. Microbiol.
45 501-510 [PubMed] 4. Pandey, D. P., and Gerdes, K. (2005. )
Nucleic Acids Res. 33
966-976 [PubMed] 5. Shah, D., Zhang, Z., Khodursky, A., Kaldalu, N., Kurg, K., and
Lewis, K. (2006. ) BMC Microbiol.
6 53. [PubMed] 6. Gerdes, K., Rasmussen, P. B., and Molin, S. (1986. )
Proc. Natl. Acad. Sci. U. S. A.
83
3116-3120 [PubMed] 7. Yarmolinsky, M. B. (1995. )
Science 267
836-837 [PubMed] 8. Szekeres, S., Dauti, M., Wilde, C., Mazel, D., and Rowe-Magnus, D.
A. (2007. ) Mol. Microbiol.
63
1588-1605 [PubMed] 9. Loris, R., Marianovsky, I., Lah, J., Laeremans, T.,
Engelberg-Kulka, H., Glaser, G., Muyldermans, S., and Wyns, L.
(2003. ) J. Biol. Chem.
278
28252-28257 [PubMed] 10. Madl, T., Van Melderen, L., Mine, N., Respondek, M., Oberer, M.,
Keller, W., Khatai, L., and Zangger, K. (2006. ) J. Mol.
Biol. 364
170-185 [PubMed] 11. Oberer, M., Zangger, K., Gruber, K., and Keller, W.
(2007. ) Protein Sci.
16
1676-1688 [PubMed] 12. Lehnherr, H., Maguin, E., Jafri, S., and Yarmolinsky, M. B.
(1993. ) J. Mol. Biol.
233
414-428 [PubMed] 13. Liu, M., Zhang, Y., Inouye, M., and Woychik, N. A.
(2008. ) Proc. Natl. Acad. Sci. U. S. A.
105
5885-5890 [PubMed] 14. McKinley, J. E., and Magnuson, R. D. (2005. )
J. Bacteriol. 187
765-770 [PubMed] 15. Smith, J. A., and Magnuson, R. D. (2004. ) J.
Bacteriol. 186
2692-2698 [PubMed] 16. Gazit, E., and Sauer, R. T. (1999. ) J. Biol.
Chem. 274
16813-16818 [PubMed] 17. Gazit, E., and Sauer, R. T. (1999. ) J. Biol.
Chem. 274
2652-2657 [PubMed] 18. Magnuson, R., Lehnherr, H., Mukhopadhyay, G., and Yarmolinsky, M.
B. (1996. ) J. Biol. Chem.
271
18705-18710 [PubMed] 19. Magnuson, R., and Yarmolinsky, M. B. (1998. )
J. Bacteriol. 180
6342-6351 [PubMed] 20. Otwinowski, Z., and Minor, W. (1997. )
Methods Enzymol. 276
307-326. 21. Schneider, T. R., and Sheldrick, G. M. (2002. )
Acta Crystallogr. Sect. D Biol. Crystallogr.
58
1772-1779 [PubMed] 22. Panjikar, S., Parthasarathy, V., Lamzin, V. S., Weiss, M. S., and
Tucker, P. A. (2005. ) Acta Crystallogr. Sect. D Biol.
Crystallogr. 61
449-457 [PubMed] 23. Morris, R. J., Perrakis, A., and Lamzin, V. S. (2003. )
Methods Enzymol. 374
229-244 [PubMed] 24. Murshudov, G. N., Vagin, A. A., and Dodson, E. J.
(1997. ) Acta Crystallogr. Sect. D Biol.
Crystallogr. 53
240-255 [PubMed] 25. Dam, M., and Gerdes, K. (1994. ) J. Mol.
Biol. 236
1289-1298 [PubMed] 26. Watson, J. D., and Milner-White, E. J. (2002. )
J. Mol. Biol. 315
171-182 [PubMed] 27. Kamada, K., and Hanaoka, F. (2005. ) Mol.
Cell 19
497-509 [PubMed] 28. Takagi, H., Kakuta, Y., Okada, T., Yao, M., Tanaka, I., and Kimura,
M. (2005. ) Nat. Struct. Mol. Biol.
12 327-331 [PubMed] 29. Anantharaman, V., and Aravind, L. (2003. )
Genome Biol. 4
R81. [PubMed] 30. Hazan, R., Sat, B., Reches, M., and Engelberg-Kulka, H.
(2001. ) J. Bacteriol.
183
2046-2050 [PubMed] 31. Zhang, Y., Zhang, J., Hoeflich, K. P., Ikura, M., Qing, G., and
Inouye, M. (2003. ) Mol. Cell
12 913-923 [PubMed] 32. Studier, F. W., and Moffatt, B. A. (1986. )
J. Mol. Biol. 189
113-130 [PubMed] 33. Utsumi, R., Nakamoto, Y., Kawamukai, M., Himeno, M., and Komano, T.
(1982. ) J. Bacteriol.
151
807-812 [PubMed] 34. Kawamukai, M., Matsuda, H., Fujii, W., Utsumi, R., and Komano, T.
(1989. ) J. Bacteriol.
171
4525-4529 [PubMed] 35. Remaut, H., and Waksman, G. (2006. ) Trends
Biochem. Sci. 31
436-444 [PubMed] 36. Sauer, F. G., Futterer, K., Pinkner, J. S., Dodson, K. W.,
Hultgren, S. J., and Waksman, G. (1999. )
Science 285
1058-1061 [PubMed] 37. Yan, Y., Li, Y., Munshi, S., Sardana, V., Cole, J. L., Sardana, M.,
Steinkuehler, C., Tomei, L., De Francesco, R., Kuo, L. C., and Chen, Z.
(1998. ) Protein Sci.
7 837-847 [PubMed] 38. Christensen, S. K., and Gerdes, K. (2003. )
Mol. Microbiol. 48
1389-1400 [PubMed] 39. Livingstone, C. D., and Barton, G. J. (1993. )
Comput. Appl. Biosci. 9
745-756 [PubMed] 40. Marti-Renom, M. A., Madhusudhan, M. S., and Sali, A.
(2004. ) Protein Sci.
13
1071-1087 [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Trends Biochem Sci. 2005 Dec; 30(12):672-9.
[Trends Biochem Sci. 2005]Mol Microbiol. 2002 Jul; 45(2):501-10.
[Mol Microbiol. 2002]Nucleic Acids Res. 2005; 33(3):966-76.
[Nucleic Acids Res. 2005]BMC Microbiol. 2006 Jun 12; 6():53.
[BMC Microbiol. 2006]Proc Natl Acad Sci U S A. 1986 May; 83(10):3116-20.
[Proc Natl Acad Sci U S A. 1986]Science. 1995 Feb 10; 267(5199):836-7.
[Science. 1995]Mol Microbiol. 2007 Mar; 63(6):1588-605.
[Mol Microbiol. 2007]J Biol Chem. 2003 Jul 25; 278(30):28252-7.
[J Biol Chem. 2003]Protein Sci. 2007 Aug; 16(8):1676-88.
[Protein Sci. 2007]J Mol Biol. 1993 Oct 5; 233(3):414-28.
[J Mol Biol. 1993]Proc Natl Acad Sci U S A. 2008 Apr 15; 105(15):5885-90.
[Proc Natl Acad Sci U S A. 2008]J Bacteriol. 2005 Jan; 187(2):765-70.
[J Bacteriol. 2005]J Bacteriol. 2004 May; 186(9):2692-8.
[J Bacteriol. 2004]J Biol Chem. 1999 Jun 11; 274(24):16813-8.
[J Biol Chem. 1999]Acta Crystallogr D Biol Crystallogr. 2002 Oct; 58(Pt 10 Pt 2):1772-9.
[Acta Crystallogr D Biol Crystallogr. 2002]Acta Crystallogr D Biol Crystallogr. 2005 Apr; 61(Pt 4):449-57.
[Acta Crystallogr D Biol Crystallogr. 2005]Methods Enzymol. 2003; 374():229-44.
[Methods Enzymol. 2003]Acta Crystallogr D Biol Crystallogr. 1997 May 1; 53(Pt 3):240-55.
[Acta Crystallogr D Biol Crystallogr. 1997]J Mol Biol. 1994 Mar 11; 236(5):1289-98.
[J Mol Biol. 1994]J Bacteriol. 1998 Dec; 180(23):6342-51.
[J Bacteriol. 1998]J Bacteriol. 2005 Jan; 187(2):765-70.
[J Bacteriol. 2005]J Bacteriol. 2004 May; 186(9):2692-8.
[J Bacteriol. 2004]J Mol Biol. 2002 Jan 11; 315(2):171-82.
[J Mol Biol. 2002]J Bacteriol. 1998 Dec; 180(23):6342-51.
[J Bacteriol. 1998]J Bacteriol. 2005 Jan; 187(2):765-70.
[J Bacteriol. 2005]J Bacteriol. 2004 May; 186(9):2692-8.
[J Bacteriol. 2004]Mol Cell. 2005 Aug 19; 19(4):497-509.
[Mol Cell. 2005]Nat Struct Mol Biol. 2005 Apr; 12(4):327-31.
[Nat Struct Mol Biol. 2005]Genome Biol. 2003; 4(12):R81.
[Genome Biol. 2003]Comput Appl Biosci. 1993 Dec; 9(6):745-56.
[Comput Appl Biosci. 1993]J Bacteriol. 1998 Dec; 180(23):6342-51.
[J Bacteriol. 1998]Comput Appl Biosci. 1993 Dec; 9(6):745-56.
[Comput Appl Biosci. 1993]J Bacteriol. 1998 Dec; 180(23):6342-51.
[J Bacteriol. 1998]J Mol Biol. 1993 Oct 5; 233(3):414-28.
[J Mol Biol. 1993]Proc Natl Acad Sci U S A. 2008 Apr 15; 105(15):5885-90.
[Proc Natl Acad Sci U S A. 2008]J Bacteriol. 2001 Mar; 183(6):2046-50.
[J Bacteriol. 2001]Mol Cell. 2003 Oct; 12(4):913-23.
[Mol Cell. 2003]J Mol Biol. 1986 May 5; 189(1):113-30.
[J Mol Biol. 1986]J Mol Biol. 1993 Oct 5; 233(3):414-28.
[J Mol Biol. 1993]Protein Sci. 2004 Apr; 13(4):1071-87.
[Protein Sci. 2004]Protein Sci. 2004 Apr; 13(4):1071-87.
[Protein Sci. 2004]Proc Natl Acad Sci U S A. 2008 Apr 15; 105(15):5885-90.
[Proc Natl Acad Sci U S A. 2008]J Bacteriol. 1982 Aug; 151(2):807-12.
[J Bacteriol. 1982]J Bacteriol. 1989 Aug; 171(8):4525-9.
[J Bacteriol. 1989]J Mol Biol. 1993 Oct 5; 233(3):414-28.
[J Mol Biol. 1993]Trends Biochem Sci. 2006 Aug; 31(8):436-44.
[Trends Biochem Sci. 2006]Science. 1999 Aug 13; 285(5430):1058-61.
[Science. 1999]Protein Sci. 1998 Apr; 7(4):837-47.
[Protein Sci. 1998]Mol Microbiol. 2003 Jun; 48(5):1389-400.
[Mol Microbiol. 2003]